Drug Trial Radar · NCT03845712
An Open-Label Study of Continuation Treatment With Combination Pyrimidine Nucleosides in Patients With TK2 Deficiency
Last checked: Nov 19, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
47
Actual
Start
Jul 5, 2019
Primary completion
Aug 26, 2026
Study completion Aug 26, 2026
Sponsor
- Lead sponsor
- UCB BIOSCIENCES, Inc.UCB
- Sponsor type
- Industry
- First posted
- Feb 19, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2 prospective open-label treatment study of the safety and efficacy of doxecitine and doxribtimine in study participants with thymidine kinase 2 (TK2) deficiency who participated in the retrospective study MT-1621-101 \[NCT03701568\] or who were receiving nucleos(t)ide treatment and were approved by the Sponsor.
Conditions
- Thymidine Kinase 2 Deficiency
Interventions
doxecitine and doxribtimineDrug
Doxecitine and doxribtimine is administered orally in 3 equal doses given approximately 6 to 8 hours apart. Doxecitine and doxribtimine is administered with food.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent adverse events (TEAEs)Time frame: From first administration of study drug until end of safety follow-up (up to approximately 7 years)
- Incidence of TEAEs leading to study drug withdrawalTime frame: From first administration of study drug until end of safety follow-up (up to approximately 7 years)
Locations
8 sites in 3 countries. Site status is shown where the registry gives one.
Tk0102 1005
New York, New York
Tk0102 4038
Haifa, Israel
Tk0102 4039
Holon, Israel
Tk0102 4037
Nehariya, Israel
Tk0102 3102
Barcelona, Spain
Tk0102 3121
Esplugues de Llobregat, Spain
Tk0102 3031
Madrid, Spain
Tk0102 3101
Seville, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.